Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: A single-centre study with focus on emerging pathogens

Mycoses

Volumn 58, Issue 6, 2015, Pages 325-336

  Corzo León, Dora E ^a,b   Satlin, Michael J ^b   Soave, Rosemary ^b   Shore, Tsiporah B ^b   Schuetz, Audrey N ^b   Jacobs, Samantha E ^b   Walsh, Thomas J ^b  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Allogeneic stem cell transplantation; Invasive fungal infections

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; THYMOCYTE ANTIBODY; VORICONAZOLE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL PROPHYLAXIS; ANTIFUNGAL SUSCEPTIBILITY; ARTHROGRAPHIS; ARTICLE; CANCER PATIENT; CENTRAL VENOUS CATHETER; CLADOSPORIUM; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FUNGEMIA; GEOSMITHIA ARGILLACEA; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HORMOGRAPHIELLA ASPERGILLATA; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MUCORALES; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SYSTEMIC DISEASE; SYSTEMIC MYCOSIS; TRICHOSPORON ASAHII; YOUNG ADULT; ALLOTRANSPLANTATION; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CHEMOPROPHYLAXIS; CLASSIFICATION; FUNGUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOCOMPROMISED PATIENT; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORTALITY; PROCEDURES; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ARTHROGRAPHIS; CLADOSPORIUM; CYTOMEGALOVIRUS; FUNGI; GEOSMITHIA ARGILLACEA; MUCORALES; TRICHOSPORON ASAHII;

ADULT; ANTIFUNGAL AGENTS; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM FUNGAL INFECTIONS; CHEMOPREVENTION; FEMALE; FUNGEMIA; FUNGI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84929468170     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12318     Document Type: Article

References (44)

1. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48: 265-73.
2. Kontoyiannis DP, Marr KA, Park BJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-100.
3. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-33.
4. Pagano L, Caira M, Nosari A et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study-Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45: 1161-70.
5. Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-18.
6. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-47.
7. Pagano L, Caira M, Nosari A et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica 2011; 96: 1366-70.
8. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
9. Van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
10. Lamoth F, Cruciani M, Mengoli C et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54: 633-43.
11. Kawazu M, Kanda Y, Nannya Y et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1->3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with hematologic disorders. J Clin Microbiol 2004; 42: 2733-41.
12. Maertens J, Maertens V, Theunissen K et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49: 1688-93.
13. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
14. Larone DH. Medically Important Fungi: A Guide to Identification, 5th ed. Washington, DC: ASM Press, 2011.
15. Nucci M, Garnica M, Gloria AB et al. Invasive fungal diseases in hematopoietic cell transplant recipients and in patients with acute myeloid leukemia or myelodysplasia in Brazil. Clin Microbiol Infect 2013; 19: 745-51.
16. Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 2002; 44: 11-16.
17. Blanchard E, Lortholary O, Boukris-Sitbon K et al. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother 2011; 55: 5358-61.
18. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48: 2373-80.
19. Gamaletsou MN, Walsh TJ, Zaoutis T et al. A prospective, cohort, multicenter study on candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect 2014; 20: O50-57.
20. Park BJ, Pappas PG, Wannemuehler KA et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17: 1855-64.
21. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47: 1041-50.
22. Xhaard A, Lanternier F, Porcher R et al. Mucormycosis after allogeneic hematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008). Clin Microbiol Infect 2012; 18: E396-400.
23. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis 2012; 54(Suppl. 1): S61-66.
24. Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence 2011; 2: 348-55.
25. Dua V, Yadav SP, Oberoi J, Sachdeva A. Successful treatment of Trichosporon asahii infection with voriconazole after bone marrow transplant. J Pediatr Hematol Oncol 2013; 35: 237-8.
26. Agirbasli H, Bilgen H, Ozcan SK et al. Two possible cases of Trichosporon infections in bone-marrow-transplanted children: the first case of T. japonicum isolated from clinical specimens. Jpn J Infect Dis 2008; 61: 130-2.
27. Ghiasian SA, Maghsood AH, Mirhendi SH. Disseminated, fatal Trichosporon asahii infection in a bone marrow transplant recipient. J Microbiol Immunol Infect 2006; 39: 426-9.
28. Moretti-Branchini ML, Fukushima K, Schreiber AZ et al. Trichosporon species infection in bone marrow transplanted patients. Diagn Microbiol Infect Dis 2001; 39: 161-4.
29. Walsh TJ, Lee JW, Melcher GP et al. Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis 1992; 166: 121-33.
30. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl. 1): 48-66.
31. Girmenia C, Pagano L, Martino B et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43: 1818-28.
32. Suzuki K, Nakase K, Kyo T et al. Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Hematol 2010; 84: 441-7.
33. Vos CG, Murk JL, Hartemink KJ, Daniels JM, Paul MA, Debets-Ossenkopp YJ. A rare pulmonary infection caused by Arthrographis kalrae. J Med Microbiol 2012; 61: 593-5.
34. Safdar A, Singhal S, Mehta J. Clinical significance of non-Candida fungal blood isolation in patients undergoing high-risk hematopoietic stem cell transplantation (1993-2001). Cancer 2004; 100: 2456-61.
35. Houbraken J, Giraud S, Meijer M et al. Taxonomy and antifungal susceptibility of clinically important Rasamsonia species. J Clin Microbiol 2013; 51: 22-30.
36. De Ravin SS, Challipalli M, Anderson V et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis 2011; 52: e136-43.
37. Giraud S, Pihet M, Razafimandimby B et al. Geosmithia agrillacea: an emerging pathogen in patients with cystic fibrosis. J Clin Microbiol 2010; 48: 2381-6.
38. Valentin T, Neumeister P, Pichler M et al. Disseminated Geosmithia agrillacea infection in a patient with gastrointestinal GVHD. Bone Marrow Transplant 2012; 47: 734-6.
39. Conen A, Weisser M, Hohler D, Frei R, Stern M. Hormographiella aspergillata: an emerging mould in acute leukemia patients? Clin Microbiol Infect 2011; 17: 273-7.
40. Suarez F, Olivier G, Garcia-Hermoso D et al. Breakthrough Hormographiella aspergillata infections arising in neutropenic patients treated empirically with caspofungin. J Clin Microbiol 2011; 49: 461-5.
41. Jacobs SE, Soave R, Shore TB et al. Human rhinovirus infections of the lower respiratory tract in hematopoietic stem cell transplant recipients. Transpl Infect Dis 2013; 15: 474-86.
42. Jacobs SE, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. Clin Microbiol Rev 2013; 26: 135-62.
43. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
44. Baddley JW, Andes DR, Marr KA et al. Factors associated with mortality in transplant recipients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-67.